Palladone (Hydromorphone Hydrochloride)

Hydromorphone hydrochloride is an opioid that acts on the central nervous system to relieve pain in several clinical contexts.

• Cancer‑related pain: Provides strong analgesia for patients with malignant disease when other opioids are insufficient.
• Post‑operative pain: Controls acute pain following major surgical procedures.
• Severe chronic non‑cancer pain: Offers long‑term relief for patients with debilitating chronic pain unresponsive to weaker analgesics.

• Hydromorphone hydrochloride binds selectively to μ‑opioid receptors in the central nervous system, mimicking the action of endogenous opioids. This receptor activation inhibits the release of excitatory neurotransmitters, reduces neuronal excitability, and alters pain perception pathways, resulting in potent analgesic effects.

Adverse reactions to hydromorphone may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach and urge to vomit.
• Constipation: reduced bowel motility leading to hard stools.
• Drowsiness: feeling unusually sleepy or fatigued.
• Dizziness: light‑headed sensation, especially when standing quickly.
• Dry mouth: reduced salivation causing a parched feeling.
• Sweating: increased perspiration without exertion.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing that can be life‑threatening.
• Severe hypotension: marked drop in blood pressure causing faintness.
• Cardiac arrhythmias: irregular heart rhythms that may require medical attention.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Dependence and withdrawal: physical dependence developing with prolonged use.
• adrenal insufficiency: rare hormonal imbalance affecting stress response.

When prescribing hydromorphone, clinicians should consider several safety measures.

• Assess pain severity and prior opioid exposure: ensure appropriate indication before initiating therapy.
• Monitor for respiratory depression: especially during dose titration and in opioid‑naïve patients.
• Evaluate renal and hepatic function: adjust dosing in patients with impairment.
• Avoid concurrent central nervous system depressants: limit additive sedation risk.
• Educate patients on constipation management: use laxatives or stool softeners as needed.
• Store at ambient temperature: keep below 25°C in the original container, protected from moisture and direct sunlight.

Hydromorphone may interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Benzodiazepines: combined use can cause profound respiratory depression and excessive sedation.
• Barbiturates: may potentiate central nervous system depression, increasing overdose risk.
• Muscle relaxants: additive sedative effects can impair respiration and cognition.

Moderate Interactions (Monitor Closely)

• Antidepressants (SSRIs, SNRIs): may increase serotonin levels and risk of serotonin syndrome.
• Anticholinergic agents: can exacerbate constipation and urinary retention.
• CYP3A4 inhibitors (e.g., ketoconazole): may raise hydromorphone plasma concentrations.